Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Correcting Age-Related Overactive Bladder Syndrome by Inhibiting Matrix Metallopeptidase-9 Overexpression
EF 2020-21
Résumé
Overactive bladder syndrome (OAB) is characterized by the loss of bladder control and the frequent urge to urinate, interfering with daily life activities, such as sleep, work and leisure, which reduces the quality of life. OAB affects around 20% of the Canadian adults and increases in prevalence with age. Although the underlying causes of OAB are unknown, a recent study has shown that aging females with OAB exhibit lower levels of a protein, Nerve Growth Factor (NGF), in their urine. NGF is essential for nervous system health. Since the bladder is under strict control of the nervous system, the decrease in NGF reduces the neurological control of the bladder and poor control of urine storage and release. Decreased NGF may be explained by an increased activity of Matrix Metallopeptidase-9 (MMP-9), an enzyme responsible for degrading NGF. MMP-9 activity is regulated by microRNAs, biological molecules that play a role in controlling gene expression. The microRNA, miR-491-5p, inhibits MMP-9 gene expression to prevent NGF degradation. In the urine of aging females with OAB, MMP-9 activity is increased and miR-491-5p levels are reduced, likely explaining the reduced NGF levels. Thus, controlling MMP-9 may restore NGF levels and reverse OAB. Our study aims to inhibit the activity of MMP-9 to correct OAB through administration of miR-491-5p mimics in mouse models of age-related OAB. We hypothesize that miR-591-5p mimics will prevent the synthesis of MMP-9, restoring adequate NGF levels to correct OAB in aging mice. Most of our preliminary data are derived from a cohort of human patients. The clinical implication of this study lies in our assessment of the functional benefit of restoring bladder NGF in aging mice with OAB, which may enable future treatments for age-related OAB.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
449451
Name
Hamouda Aalya
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Correcting Age-Related Overactive Bladder Syndrome by Inhibiting Matrix Metallopeptidase-9 Overexpression
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Age; Bladder Dysfunction; Matrix Metallopeptidase-9; Microrna Therapy; Nerve Growth Factor; Neurodegeneration; Overactive Bladder Syndrome; Therapeutic Agent; Translational Research
Abstract
Overactive bladder syndrome (OAB) is characterized by the loss of bladder control and the frequent urge to urinate, interfering with daily life activities, such as sleep, work and leisure, which reduces the quality of life. OAB affects around 20% of the Canadian adults and increases in prevalence with age. Although the underlying causes of OAB are unknown, a recent study has shown that aging females with OAB exhibit lower levels of a protein, Nerve Growth Factor (NGF), in their urine. NGF is essential for nervous system health. Since the bladder is under strict control of the nervous system, the decrease in NGF reduces the neurological control of the bladder and poor control of urine storage and release. Decreased NGF may be explained by an increased activity of Matrix Metallopeptidase-9 (MMP-9), an enzyme responsible for degrading NGF. MMP-9 activity is regulated by microRNAs, biological molecules that play a role in controlling gene expression. The microRNA, miR-491-5p, inhibits MMP-9 gene expression to prevent NGF degradation. In the urine of aging females with OAB, MMP-9 activity is increased and miR-491-5p levels are reduced, likely explaining the reduced NGF levels. Thus, controlling MMP-9 may restore NGF levels and reverse OAB. Our study aims to inhibit the activity of MMP-9 to correct OAB through administration of miR-491-5p mimics in mouse models of age-related OAB. We hypothesize that miR-591-5p mimics will prevent the synthesis of MMP-9, restoring adequate NGF levels to correct OAB in aging mice. Most of our preliminary data are derived from a cohort of human patients. The clinical implication of this study lies in our assessment of the functional benefit of restoring bladder NGF in aging mice with OAB, which may enable future treatments for age-related OAB.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hamouda, Aalya
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~